Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

The open-label, dose-escalation study will investigate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302 for the given indication. The study is designed to identify the optimal dosage of BEAM302. BEAM received clearance for its clinical trial authorization application from the United Kingdom Medicines and Healthcare Products Regulatory Agency for BEAM-302 in March 2024. BEAM is also developing another pipeline candidate in its genetic disease portfolio, BEAM-301. The company is looking ...